loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Sovleplenib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Sovleplenib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED Highlights Sovleplenib, Hematology Data At Upcoming EHA 2024
    HUTCHMED Highlights Sovleplenib, Hematology Data At Upcoming EHA 2024

    16 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/17/2883983/0/en/HUTCHMED-Highlights-Sovleplenib-Phase-III-ESLIM-01-Study-and-Hematological-Malignancy-Programs-Data-to-be-Presented-at-the-upcoming-EHA2024-Congress.html

    GLOBENEWSWIRE
    16 May 2024
    Share Share
    Hutchmed Announces NDA Acceptance in China for Sovleplenib
    Hutchmed Announces NDA Acceptance in China for Sovleplenib

    10 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/11/2807571/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-for-Sovleplenib-for-the-Treatment-of-Primary-Immune-Thrombocytopenia-with-Priority-Review-Status.html

    GLOBENEWSWIRE
    10 Jan 2024
    Share Share
    Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia
    Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

    24 Aug 2023

    // ONCLIVE

    https://www.onclive.com/view/sovleplenib-elicits-durable-responses-in-primary-immune-thrombocytopenia

    ONCLIVE
    24 Aug 2023
    Share Share
    HUTCHMED Announces that Sovleplenib PIII ESLIM-01 Study Met Its Primary Endpoint
    HUTCHMED Announces that Sovleplenib PIII ESLIM-01 Study Met Its Primary Endpoint

    21 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/08/21/2728359/0/en/HUTCHMED-Announces-that-the-Sovleplenib-Phase-III-ESLIM-01-Study-Met-Its-Primary-Endpoint-in-Primary-Immune-Thrombocytopenia-in-China.html

    GLOBENEWSWIRE
    21 Aug 2023
    Share Share
    HUTCHMED Completes Patient Enrollment of ESLIM-01, a Ph III Trial of Sovleplenib
    HUTCHMED Completes Patient Enrollment of ESLIM-01, a Ph III Trial of Sovleplenib

    03 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/03/2581851/0/en/HUTCHMED-Completes-Patient-Enrollment-of-ESLIM-01-a-Phase-III-Trial-of-Sovleplenib-in-Primary-Immune-Thrombocytopenia-in-China.html

    GLOBENEWSWIRE
    03 Jan 2023
    Share Share